A Liquid Biopsy Assay for Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer.

BACKGROUND & AIMS We recently reported use of tissue-based transcriptomic biomarkers (miRNA or mRNA) for identification of lymph node metastasis (LNM) in patients with invasive submucosal colorectal cancers (T1 CRC). In this study, we translated our tissue-based biomarkers into a blood-based liquid biopsy assay for noninvasive detection of LNM in patients with high-risk T1 CRC. METHODS We analyzed 330 specimens from patients with high-risk T1 CRC, which included 188 serum samples from two clinical cohorts (training cohort: n=46, validation cohort: n=142) and matched FFPE samples (n=142). We performed RT-qPCR followed by logistic regression analysis to develop an integrated transcriptomic panel and establish a risk-stratification model, combined with clinical risk factors. RESULTS We used comprehensive expression profiling of a training cohort of LNM-positive and -negative serum specimens to identify an optimized transcriptomic panel of four miRNAs (miR-181b, miR-193b, miR-195, miR-411) and five mRNAs (AMT, FOXA1, PIGR, MMP1, MMP9), which robustly identified patients with LNM (area under the curve [AUC]=0.86, 95% CI=0.72-0.94). We validated panel performance in an independent validation cohort (AUC=0.82, 95% CI=0.74-0.88). Our risk-stratification model was more accurate than the panel and an independent predictor for identification of LNM (AUC=0.90, Univariate: odds ratio [OR]=37.17, 95% CI=4.48-308.35, P<.001; Multivariate: OR=17.28, 95% CI=1.82-164.07, P=.013). The model limited potential overtreatment to only 18% of all patients, which is dramatically superior to currently used pathological features (92%). CONCLUSIONS A novel risk-stratification model for noninvasive identification of T1 CRC has the potential to avoid unnecessary surgeries for patients classified as high-risk by conventional risk-classification criteria.

[1]  J. Tuynman,et al.  Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study , 2020, Modern Pathology.

[2]  E. Dekker,et al.  Suboptimal endoscopic cancer recognition in colorectal lesions in a national bowel screening programme , 2019, Gut.

[3]  T. Sugino,et al.  Associations Between Loss of ARID1A Expression and Clinicopathologic and Genetic Variables in T1 Early Colorectal Cancer. , 2019, American journal of clinical pathology.

[4]  P. Saliou,et al.  Histopathological factors help to predict lymph node metastases more efficiently than extra-nodal recurrences in submucosa invading pT1 colorectal cancer , 2019, Scientific Reports.

[5]  F. Gao,et al.  Gene Expression Signature in Surgical Tissues and Endoscopic Biopsies Identifies High-Risk T1 Colorectal Cancers. , 2019, Gastroenterology.

[6]  T. Churchill,et al.  Analysis of postdischarge costs following emergent general surgery in elderly patients. , 2018, Canadian journal of surgery. Journal canadien de chirurgie.

[7]  J. Fleshman,et al.  A MicroRNA Signature Associated With Metastasis of T1 Colorectal Cancers to Lymph Nodes. , 2017, Gastroenterology.

[8]  Min Jung Kim,et al.  Histopathologic risk factors for lymph node metastasis in patients with T1 colorectal cancer , 2017, Annals of surgical treatment and research.

[9]  K. Chayama,et al.  Long-term outcomes after treatment for T1 colorectal carcinoma: a multicenter retrospective cohort study of Hiroshima GI Endoscopy Research Group , 2017, Journal of Gastroenterology.

[10]  P. Siersema,et al.  Endoscopic resection of high-risk T1 colorectal carcinoma prior to surgical resection has no adverse effect on long-term outcomes , 2016, Gut.

[11]  Y. Toiyama,et al.  Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Eun Hye Kim,et al.  The risk of lymph node metastasis makes it unsafe to expand the conventional indications for endoscopic treatment of T1 colorectal cancer , 2016, Medicine.

[13]  M. Fujishiro,et al.  Outcome of salvage surgery for colorectal cancer initially treated by upfront endoscopic therapy. , 2016, Surgery.

[14]  R. Warschkow,et al.  Predictors for regional lymph node metastasis in T1 rectal cancer: a population-based SEER analysis , 2016, Surgical Endoscopy.

[15]  I. Christensen,et al.  Intra-tumor heterogeneity of microRNA-92a, microRNA-375 and microRNA-424 in colorectal cancer. , 2016, Experimental and molecular pathology.

[16]  Y. Toiyama,et al.  Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer , 2015, Gut.

[17]  M. Rugge,et al.  Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline , 2015, Endoscopy.

[18]  Masahiro Yoshida,et al.  JGES guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection , 2015, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[19]  Masahiro Yoshida,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer , 2011, International Journal of Clinical Oncology.

[20]  Y. Toiyama,et al.  Serum miR-200c Is a Novel Prognostic and Metastasis-Predictive Biomarker in Patients With Colorectal Cancer , 2014, Annals of surgery.

[21]  T. Joh,et al.  Magnifying chromoendoscopy and endoscopic ultrasonography measure invasion depth of early stage colorectal cancer with equal accuracy on the basis of a prospective trial. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  K. Kaneko,et al.  A large-scale multicenter study of long-term outcomes after endoscopic resection for submucosal invasive colorectal cancer , 2013, Endoscopy.

[23]  Y. Toiyama,et al.  Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. , 2013, Journal of the National Cancer Institute.

[24]  K. Kaneko,et al.  Long-term outcomes after resection for submucosal invasive colorectal cancers. , 2013, Gastroenterology.

[25]  S. Rai,et al.  Plasma MiR-21: A Potential Diagnostic Marker of Colorectal Cancer , 2012, Annals of surgery.

[26]  K. Chayama,et al.  Management of T1 colorectal carcinoma with special reference to criteria for curative endoscopic resection , 2012, Journal of gastroenterology and hepatology.

[27]  M. Kim,et al.  Predictors for lymph node metastasis in T1 colorectal cancer , 2012, Endoscopy.

[28]  M. Mukai,et al.  Risk Factors for Postoperative Recurrence in Patients with Pathologically T1 Colorectal Cancer , 2012, World Journal of Surgery.

[29]  Zhaohui Huang,et al.  Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer , 2010, International journal of cancer.

[30]  Tadakazu Shimoda,et al.  Pathological prognostic factors predicting lymph node metastasis in submucosal invasive (T1) colorectal carcinoma , 2010, Modern Pathology.

[31]  Seung-Yong Jeong,et al.  Indications for Subsequent Surgery After Endoscopic Resection of Submucosally Invasive Colorectal Carcinomas: A Prospective Cohort Study , 2009, Diseases of the colon and rectum.

[32]  E. Ng,et al.  Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening , 2009, Gut.

[33]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[34]  S. H. Park,et al.  Characteristics of early colorectal carcinoma with lymph node metastatic disease. , 2008, Hepato-gastroenterology.

[35]  M. Stamos,et al.  Management of Early Rectal T1 and T2 Cancers , 2007, Clinical Cancer Research.

[36]  D. Rothenberger,et al.  Population-based analyses of lymph node metastases in colorectal cancer. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[37]  Dong Hyun Choi,et al.  Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type , 2006, Journal of Clinical Pathology.

[38]  David M Studdert,et al.  Defensive medicine among high-risk specialist physicians in a volatile malpractice environment. , 2005, JAMA.

[39]  J. Guillem,et al.  Lymph node metastasis in T1 adenocarcinoma of the colon and rectum , 2004, Journal of Gastrointestinal Surgery.

[40]  Hidetaka Mochizuki,et al.  Risk factors for an adverse outcome in early invasive colorectal carcinoma. , 2004, Gastroenterology.

[41]  H. Baba,et al.  The risk of lymph node metastasis in T1 colorectal carcinoma. , 2004, Hepato-gastroenterology.

[42]  L. Burgart,et al.  Risk of Lymph Node Metastasis in T1 Carcinoma of the Colon and Rectum , 2002, Diseases of the colon and rectum.

[43]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[44]  K. Haruma,et al.  Conditions of curability after endoscopic resection for colorectal carcinoma with submucosally massive invasion. , 2000, Oncology reports.